| Identification | Back Directory | [Name]
Polyinosinic acid-polycytidylic acid | [CAS]
24939-03-5 | [Synonyms]
polyi:c
polyi-c
Poly-Na
Poly I:Cr
poly(i+c)
nsc-120949
polycpolyi
24939-03-5
poly(ri:rc)
Polyinosinic
polyri:polyrc
poly(ri).(rc)
POLY(I) POLY(C)
poly(ri).poly(rc)
Poly(I:C) (~90%)
Polyinosinic acid-po
Poly inosine-cytidine
poly(i).poly(c)complex
Polyinosinic Polycytidylic
POLYCYTIDYLIC-INOSINIC ACID
Polycytidysic acid (Poly C)
Polyinosinic-polytidylin Acid.
polycytidylic-polyinosinicacid
POLYINOSINIC POLYCYTIDYLIC ACID
POLYINOSINIC-POLYCYTIDILICACIDKSALT
POLYINOSINIC ACID POLYCYTIDYLIC ACID
POLYCYTIDYLIC-INOSINIC ACID POTASSIUM
Polyadenosinic acid sodium salt，Poly A
Polyinosinic-cytidylic acid disodiuM salt
polyinosinic:polycytidylic acid copolymer
Polyinosinic acid-polycytidylic acid USP/EP/BP
Polyinosinic acid: polycytidylic acid (poly I:C)
POLYINOSINIC ACID . POLYCYTIDYLIC ACID, LYOPHILIZED
5’-inosinicacid,homopolymer,complexwith5’-cytidylicacidhomopolymer(1:
5’-Inosinicacid,homopolymer,complexwith5’-cytidylicacidhomopolymer(1:1) | [EINECS(EC#)]
1308068-626-2 | [Molecular Formula]
C19H27N7O16P2 | [MDL Number]
MFCD00131957 | [MOL File]
24939-03-5.mol | [Molecular Weight]
671.403 |
| Chemical Properties | Back Directory | [storage temp. ]
−20°C
| [solubility ]
Water (Slightly) | [form ]
Solid | [color ]
White to Off-White | [Water Solubility ]
Soluble to 3 mg/ml in water | [Stability:]
Hygroscopic | [InChIKey]
ACEVNMQDUCOKHT-WOQDZEJINA-N | [SMILES]
O[C@@H]1[C@@H]([C@@H](COP(O)(O)=O)O[C@H]1N1C=CC(N)=NC1=O)O.O[C@@H]1[C@@H]([C@@H](COP(O)(O)=O)O[C@H]1N1C=NC2C(NC=NC1=2)=O)O |&1:1,2,3,11,22,23,24,32,r| |
| Hazard Information | Back Directory | [Uses]
Poly(I:C) is a toll-like receptor 3 dsRNA inflammatory stimulant. | [Definition]
ChEBI: A mismatched double-stranded RNA with one strand being a polymer of inosinic acid, the other a polymer of cytidylic acid. | [Biological Activity]
poly (i:c), a synthetic double-stranded rna (dsrna) analog, is an immunostimulant that acts as the most potent interferon (ifn) inducer. toll-like receptor- 3 (tlr3) agonist[1].mixtures that included the tlr7/8 agonists r848 or cl075, combined with the poly (i:c), yield 3-d mature dendritic cells [2].commonly used to stimulate immune system activation in vivo. also promotes maturation of hpsc-derived cardiomyocytes[3].[1]. li y g, siripanyaphinyo u, tumkosit u, et al. poly (i:c), an agonist of toll-like receptor-3, inhibits replication of the chikungunya virus in beas-2b cells. virology journal, 2012, 9(1): 114.[2]. spranger s, javorovic m, burdek m, et al. generation of th1-polarizing dendritic cells using the tlr7/8 agonist cl075. the journal of immunology, 2010, 185(1): 738-747.[3]. biermann m1, cai w2, lang d, et al. epigenetic priming of human pluripotent stem cell-derived cardiac progenitor cells accelerates cardiomyocyte maturation. stem cells, 2019, 37(7): 910-923. | [in vivo]
Polyinosinic-polycytidylic acid (2.5-10 mg/mL, Stereotaxic injection, single dose) induces a sustained inflammatory reaction in the substantia nigra (SN) and in the dorsolateral striatum. [2].
Polyinosinic-polycytidylic acid (10 μg/mouse, Intraperitoneal injection, single dose) decreases lung tumor growth in mice[3].
Polyinosinic-polycytidylic acid (1.25 mg/kg, Intraperitoneal injection, single dose) exerts therapeutic effects against cerebral I/R injury through the downregulation of TLR4/MyD88 signaling via TLR3 in MCAO model mice[5]. | Animal Model: | lung tumor-bearing mice[3] | | Dosage: | 10 μg/mouse | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Induced a significant decrease in the growth of pulmonary metastases in tumor-bearing mice.
Reduced the amount of lung foci to ≈ 40%.
Significantly increased BAL fluid cell numbers.
Increased the level of INF-γ and IL-17A, decreased the levels of IL-13.
Increased TLR3 expression. |
| Animal Model: | Middle cerebral artery occlusion (MCAO) model mice[5] | | Dosage: | 1.25 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Reduced focal cerebral I/R injury.
Increased the expression of Bcl2, Hsp27, and Hsp70, decreased Bax expression, and reduced cellular degeneration and apoptosis.
Protected against cerebral ischemia and conferred protection against cerebral I/R injury through the downregulation of TLR4 signaling via TLR3. |
| [IC 50]
Bcl-2; Bax; IL-17A; IL-13; HSP70 | [storage]
Store at -20°C |
|
|